Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536833 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
A Phase 2 study, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
NCT02536833 is a Phase 2 study that has completed, run by Biosplice Therapeutics. The registered enrollment target is 455 participants.
The verdict
NCT02536833, a Phase 2 study, has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.
Interventions
- DRUG Placebo
- DRUG SM04690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2015-09-09 |
| Est. Completion | 2017-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536833
The ClinicalTrials.gov registry entry for NCT02536833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02536833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02536833 about?
NCT02536833 is a clinical study titled "A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects". The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.
What is the current status of trial NCT02536833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2015-09-09. Estimated completion is 2017-04-20.
What interventions are being tested in trial NCT02536833?
The interventions under investigation include: Placebo (DRUG), SM04690 (DRUG).
Who is sponsoring clinical trial NCT02536833?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.